期刊文献+

HE及免疫组化染色切片褪色后行EGFR基因突变检测 被引量:2

下载PDF
导出
摘要 随着肿瘤生物学及分子生物学的不断发展,分子靶向治疗已开启肿瘤诊疗的个体化时代。晚期非小细胞肺癌(non—small cell lung cancer,NSCLC)靶向治疗已显示一定的优越性,对于优势患者明显好于化疗的疗效,但靶向治疗必须依赖相关生物学标志物检测,尤其一线靶向治疗生物学检测更为重要。
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2016年第5期585-587,共3页 Chinese Journal of Clinical and Experimental Pathology
基金 国家自然科学基金青年基金(81201759) 云南省应用基础研究面上项目(2012FB210)
  • 相关文献

参考文献14

  • 1李恩孝主编..恶性肿瘤分子靶向治疗[M].北京:人民卫生出版社,2011:636.
  • 2牛飞玉,吴一龙.非小细胞肺癌表皮生长因子受体酪氨酸酶激酶抑制剂的耐药机制及对策[J].肿瘤防治研究,2012,39(7):865-868. 被引量:2
  • 3Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009,361(10):947-57. 被引量:1
  • 4Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enrIHCed polymerase chain reaction assay[J]. Clin Cancer Res, 2006,12(1):43-8. 被引量:1
  • 5Zhang X, Zhao Y, Wang M, et al. Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer[J]. Lung cancer, 2008,60(2):175-82. 被引量:1
  • 6Soh J, Toyooka S, Aoe K, et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer[J]. Int J Cancer, 2006,119(10):2353-8. 被引量:1
  • 7谢强,陈群,石琴,孙卫红,钟爱虹,林江平,王成辉.内科胸腔镜非小细胞肺癌活检标本及胸腔积液中EG-FR基因突变检测[J].临床与实验病理学杂志,2013,29(8):881-883. 被引量:6
  • 8Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients[J]. Cancer Sei, 2006,97(7):642-8. 被引量:1
  • 9Wu S G, Gow C H, Yu C J, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma[J]. Eur Respir J, 2008,32(4):924-30. 被引量:1
  • 10王伯沄等主编..病理学技术[M].北京:人民卫生出版社,2000:1122.

二级参考文献35

  • 1lnukai M,Toyooka S,Ito S,et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non- small cell lung cancer[J]. Cancer Res,2006,66(16) :7854-8. 被引量:1
  • 2Eck MJ ,Yun CH. Structural and mechanistic underpinnings of 1he differential drug sensitivity of EGFR mutations in non small cell lung cancer[J]. Biochirn Biophys Acta, 2010, 1814 (3) : 559-66. 被引量:1
  • 3Yun CH, Mengwasser KE, Toms AV, et al. The T79ilM muta tion in EGFR kinase causes drug resistance by increasing the affinity for ATP[J].Proc Natl Acad Sci U S A,2008,105(6) : 2070-5. 被引量:1
  • 4Oh JE, An CH, Yoo N J, et at. Detection of fow-level EGFR T790M mutation in lung cancer tissues[J].APMIS, 2011, 119(7):403-11. 被引量:1
  • 5Maheswaran S,Sequist LV,Nagrath S,et al. Detection of mu talions in EGFR in circulating lung cancer eells[J]. N Engl J Med, 2008,359(4) :366-77. 被引量:1
  • 6Bean J, Riely GJ, Balak M, et al. Acquired resistance to epider real growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma[J]. Clin Cancer Res,2008,14(22) :7519-25. 被引量:1
  • 7Subramaniam [3S, Hwang J. BIBW 2992 in non-small cell lung cancer[J]. Expert Opin Investig Drugs,2011,20(3) :415-22. 被引量:1
  • 8Zhou W, Ercan D,Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M[J]. Nature, 2009,462 (7276) : lll70- 4. 被引量:1
  • 9Regales L,Gong Y,Shen R,et al. Dual target:ng of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer[J].J Clin Invest, 2009, 1 19 (10) 3000- 10. 被引量:1
  • 10l.utterbach B, Zeng Q, Davis l.J, et al. I.ung cancer cell lines harboring MET gene amplifica*ion are dependent on Met for growth and survival[J]. Cancer Res,2007,67(5):2081-8. 被引量:1

共引文献8

同被引文献9

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部